Division of Medical Oncology, Department of Internal Medicine, Gachon University School of Medicine, Gil Medical Center, Incheon, South Korea
Joo-Hwan Park , Inkeun Park , Jinju Kim , Chang Seon Lee , Kwonoh Park , Jin Young Kim , Se Hyun Kim , Il Hwan Kim , Hyo Jin Lee , Woo Kyun Bae , Seok Jae Huh , Miso Kim , Min-Young Lee , Seong Hoon Shin , Ho Young Kim , Byeong Seok Sohn , In-Ho Kim , Jae-Lyun Lee
Background: Several clinical guidelines recommend screening for hereditary prostate cancer in high-risk groups for metastatic prostate cancer. However, despite the recent increase in the diagnosis of prostate cancer in Korea, genetic testing for hereditary prostate cancer is not being performed, making it impossible to know the frequency of hereditary prostate cancer. This study aimed to determine the prevalence of germline mutations in unselected Korean patients with metastatic prostate cancer. Methods: Between July 2021 and December 2022, metastatic prostate cancer patients were enrolled prospectively, without any specific selection based on age or family history. Germline mutation analysis was performed on DNA from blood via next generation sequencing using SOLIDaccuTestTM DNA HRD (NgeneBio, Korea). Results: A total of 301 patients were enrolled and the prevalence of germline mutation was analyzed. At diagnosis, the median age was 67 (46-91 years old), and the median PSA was 150 ng/mL (3.07-5000). 250 patients had a Gleason score of 8 or higher. 36 patients (12.0 %) carried a pathogenic (14/301, 4.6 %)/likely pathogenic (22/301, 7.3 %) variant in a germline mutation. Of these patients, 11 patients (3.65 %) had BRCA2 mutations. ATM (6/301, 1.99 %) was the second most frequently mutated gene, followed by FH (4/301, 1.33 %), FANCA, FANCD2, MRE11, SLFN11, SMO (0.66 % of each, 2/301), BLM, CHEK2, ERBB3, MAP2K1, and VHL (0.33 % of each, 1/301). Further analysis will be conducted to evaluate the impact of germline mutations on somatic mutation results, treatment patterns, and clinical outcomes. Conclusions: The prevalence of pathogenic germline mutations among unselected Korean patients with metastatic prostate cancer was 12.0 %. Germline mutation prevalence in this cohort was comparable to previous reported results. This study provides the framework for the development of preventive and treatment strategies based on hereditary genetic factors for prostate cancer in the Korean population.
Mutated Gene | P/LP N (%) |
---|---|
BRCA2 | 11 (3.65 %) |
ATM | 6 (1.99 %) |
FH | 4 (1.33 %) |
FANCA, FANCD2, MRE11, SLFN11, SMO | 2 (0.66 %) |
BLM, CHEK2, ERBB3, MAP2K1, VHL | 1 (0.33 %) |
P, pathogenic; LP, likely pathogenic.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Muhammad Danyal Ahsan
2022 ASCO Genitourinary Cancers Symposium
First Author: Mari Nakazawa
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Robin Kate Kelley
2021 ASCO Annual Meeting
First Author: Silvia Gasperoni